Testing HP515 for fatty liver disease (NASH/MASH)
Part of Digestive system clinical trials.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your liver fat level is at least 10% as measured by a scan.
- You agree to use effective birth control during the study and for 6 months after.
- You do not have cirrhosis or other serious liver conditions.
- You do not have poorly controlled diabetes (HbA1c below 8.0%).
- You have not had major heart or blood vessel problems in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Hear when a new NAFLD (Non-alcoholic Fatty Liver Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.